Voyager Nabs Neurocrine As Partner In CNS Gene Therapy
Voyager signals Phase II study of gene therapy VY-AADC in Parkinson's disease is on track, with no expectations for regulatory setbacks.
You may also be interested in...
Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Neurocrine plans to advance XEN901 into Phase II in a rare pediatric epilepsy indication while eyeing opportunity in adult focal epilepsy. Xenon increases its runway to develop a pair of mid-stage epilepsy drugs.